Hawai'i Biotech Names Ian Frazer to Scientific Advisory Board

Hi, Biotech is an independent publication with no affiliation with Hawaii Biotech, Inc. This page preserves a historical record from the company's original press archive, republished for research and archival purposes. Copyright in the original material remains with its original owner.

FOR IMMEDIATE RELEASE Contact: Dr. Elliot Parks, 808-342-7281

HAWAI`I BIOTECH NAMES IAN FRAZER TO SCIENTIFIC ADVISORY BOARD

(HONOLULU, June 2, 2008) -- Hawai`i Biotech, Inc. Board of Directors and management are pleased to announce the appointment of Ian Frazer, M.D., to its Scientific Advisory Board (SAB). Professor Frazer is director of the Diamantina Institute of Cancer, Immunology and Metabolic Medicine, a research institute of the University of Queensland at the Princess Alexandra Hospital in Brisbane.

"For the past 25 years, Dr. Frazer has pursued the development of vaccines to prevent human papillomavirus (HPV) infection," says Elliot Parks, Ph.D., chief executive officer of Hawaii Biotech. "This work is the basis of vaccines to prevent cervical cancer recently brought to market by GlaxoSmithKline (CervarixTM) and Merck (GardasilTM)." The HPV vaccine is only the second vaccine to be produced using recombinant DNA technology.

"Professor Frazer's invaluable insights and experience will help move Hawaii Biotech forward more quickly as we develop our recombinant vaccines and take them through clinical testing," adds Parks.

Frazer's current research interests include immunoregulation and immunotherapeutic vaccines for papillomavirus associated cancers, for which he holds research funding from several Australian and United States funding bodies, including the National Health and Medical Research Council, the Queensland Cancer Fund and the Cancer Research Institute of New York.

Chosen the 2006 Queenslander of the Year and the 2006 Australian of the Year, Frazer is president of the Cancer Council Australia and has over many years advised the WHO on papillomavirus vaccines. He has received several prestigious awards for his pioneering work on immunology, virology and vaccine development including the John Curtin Medal, the William Coley Medal, the Florey Medal and the Novartis Prize for Clinical Immunology.

Frazer emigrated to Australia in 1981 from Edinburgh, Scotland, to continue his clinical training and to pursue studies in viral immunology and autoimmunity at the Walter and Eliza Hall Institute of Medical Research with Professor Ian Mackay.

About Hawaii Biotech, Inc. Hawaii Biotech is a privately held biotechnology company focused on the research and development of prophylactic vaccines for infectious diseases. Hawaii Biotech has developed a proprietary protein production platform that has application to the production of proteins for use as antigens in infectious disease vaccines. In addition, to its work on a West Nile vaccine, the company is also developing vaccines for dengue virus, seasonal and pandemic influenza. Hawaii Biotech is headquartered in Honolulu, Hawaii. For more information please visit: http://www.hibiotech.com.